CollPlant tobacco greenhouse, photo:PR CollPlant moves ahead on printing human organs

The company has announced a six-month agreement with "a leading medical instruments company" to develop a prototype biological implant.

Teva  photo: Reuters "Teva unlikely to remain priced below Mylan"

As Teva's share price plunges to a 15-year low, Leader Capital Markets analyst Sabina Levy provides some perspective.

EyeYon Israeli co Azura Ophthalmics raises $16m

The Tel Aviv based company's dry eye treatment is preparing for a Phase IIa trial, having shown efficacy in an initial clinical proof of concept study.

Martin Schlaff  photo: Reuters Billionaire Martin Schlaff invests in CollPlant

It was announced last month that Schlaff's company would invest $5 million in CollPlant, propelling the company's market cap up to NIS 85 million.

Dorit Salinger photo: Tamar Matzafi Long-term care insurance premiums set to rise

The increase is likely to be particularly steep for older people.

Mazor X, photo: Mazor Robotics website Mazor Robotics sells 22 systems in Q3

The spinal surgery systems company posted a record $17 million in revenue.

Lonza laboratory  photo: Reuters Swiss pharma co Lonza opening Haifa innovation center

The new center will be located in Haifa Economic Corporation's life sciences park.

Mannkind execs open TASE trading MannKind, Celsion shares skyrocket before TASE delisting

The shares have nevertheless not made up the ground lost in the two years during which they were listed on the TASE.

Avraham Baniel  photo: Rafi Kutz Israeli co DouxMatok aims to cut sugar consumption 40%

Targeted flavor delivery developer DouxMatok recently raised $8.1 million from Pitango.

Prof. Michael Sela  photo: Eyal Izhar "My intuition says Teva will get out of this"

Copaxone co-inventor Prof. Michael Sela talks to 'Globes" about what makes it a special drug.

Chaim Hurvitz Photo: Jonathan Bloom Chaim Hurvitz: Teva can realize $5b in assets

"The moment Teva's debt falls below $30 billion the situation will be different," says the Teva shareholder and former senior executive and director.

Eye Photo: Intel Israeli co CorNeat Vision unveils artificial cornea

Following successful trials with rabbits, the Ra'anana based company is moving toward first implantation in humans by mid-2018.

Dr. Ehud Marom "Copaxone price and Teva's market share will both fall 30%"

Dr Ehud Marom, former head of Teva's Copaxone business: It's a pity that Teva took all the profit from Copaxone and invested it in Allergan.

Arie Belldegrun Photo: PR "Chemotherapy will become just a bad memory"

More energetic than ever, Arie Belldegrun talks to "Globes" about Kite Pharma's remarkable journey and the future of cancer treatment.

Mori Arkin, Uri Geiger photos: Tamar Matsafi, Eyal Izhar Accelmed fattening Cogentix for sale

Accelmed seeks to replicate its success formula in urology, as portfolio company Cogentix makes a third acquisition.

Essence Group  photo: PR Smart home means safe home for seniors

Israeli company Essence develops products that enable people to keep living at home in old age.

Prof Michal Schwartz photo: Rami Zarnegar "Lady Globes" Woman of the Year: Prof. Michal Schwartz

The Weizmann Institute researcher's groundbreaking research on Alzheimer's Disease is leading to new treatment for it.

Twitter Facebook Linkedin RSS Newsletters גלובס MAD Conference 2017